SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-23-287901
Filing Date
2023-12-04
Accepted
2023-12-04 06:04:28
Documents
13
Period of Report
2023-12-01
Items
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

Document Format Files

Seq Description Document Type Size
1 8-K d622413d8k.htm   iXBRL 8-K 27032
5 GRAPHIC g622413g1202083047283.jpg GRAPHIC 4144
  Complete submission text file 0001193125-23-287901.txt   165217

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA evlo-20231201.xsd EX-101.SCH 2842
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE evlo-20231201_lab.xml EX-101.LAB 18738
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE evlo-20231201_pre.xml EX-101.PRE 11702
7 EXTRACTED XBRL INSTANCE DOCUMENT d622413d8k_htm.xml XML 3493
Mailing Address 124 WASHINGTON STREET, SUITE 101 FOXBORO MA 02035
Business Address 124 WASHINGTON STREET, SUITE 101 FOXBORO MA 02035 617-577-0300
Evelo Biosciences, Inc. (Filer) CIK: 0001694665 (see all company filings)

IRS No.: 465594527 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38473 | Film No.: 231461203
SIC: 2834 Pharmaceutical Preparations